References
- Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271–96
- Hart DNJ. Dendritic cells: unique leucocyte populations, which control the primary immune response. Blood 1997; 90: 3245–87
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52
- Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 1997; 226: 1–5
- Schadendorf D, Nestle FO. Autologous dendritic cells for treatment of advanced cancer: an update. Recent Results Cancer Res 2000; 158: 236–48
- Jonuleit H, Kuhn U, Müller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulary dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135–42
- Thurner B, Röder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223: 1–15
- Min YH, Lee ST, Choi KM, et al. Surface expression of HLA-DM on dendritic cells derived from CD34-positive bone marrow haematopoietic stem cells. Br J Haematol 2000; 110: 385–93
- Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64: 5934–7
- Szabolcs P, Avigan D, Gezelter S, et al. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 1996; 87: 4520–30
- Morse MA, Zhou LJ, Tedder TF, et al. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy. Ann Surg 1997; 226: 6–16
- Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10–16
- Nguyen XD, Eichler H, Sucker A, et al. Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients. Transfusion 2002; 42: 428–32
- Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378–84
- Kälsch T, Elmas E, Nguyen XD, et al. Enhanced coagulation activation by in vitro lipopolysaccharide challenge in patients with ventricular fibrillation complicating acute myocardial infarction. J Cardiovasc Electrophysiol 2005; 16: 858–63
- Kälsch T, Nguyen XD, Elmas E, et al. Coagulation activation and expression of CD40 ligand on platelets upon in vitro lipopolysaccharide-challenge in patients with unstable angina. Int J Cardiol 2006; 111: 217–23
- Martinson JA, Bae J, Klingemann H-G, et al. Activated platelets rapidly up-regulate CD40L expression and can effectively mature and activate autologous ex vivo differentiated DC. Cytotherapy 2004; 6: 487–97
- Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol 2005; 238: 1–9
- Katoh N, Soga F, Nara T, et al. Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clin Exp Immunol 2006; 146: 354–61
- Kissel K, Berbe Sr, Nockher A, et al. Human platelets target dendritic cell differentiation and production of proinflammatory cytokines. Transfusion 2006; 46: 818–27
- Nguyen XD, Eichler H, Dugrillon A, et al. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J Immunol Methods 2003; 275: 57–68
- Müller-Berghaus J, Kern K, Paschen A, et al. Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immun 2004; 5: 431–4
- Scandella E, Men Y, Gillessen S, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002; 100: 1354–61
- Elzey BD, Tian J, Jensen RJ, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9–19
- Danese S, de la Motte C, Reyes B.M, et al. CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplication. J Immunol 2004; 172: 2011–15
- McIlroy D, Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 2003; 52: 583–91
- Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563–70
- Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475–80
- Morrell CN, Sun H, Swaim AM, et al. Platelets: an inflammatory force in transplantation. Am J Transplant 2007; 7: 2447–54
- Somasundaram R, Satyamoorthy K, Caputo L, et al. Detection of HLA class II-dependent T helper antigen using antigen phage display. Clin Exp Immunol 2004; 135: 247–52
- elGhazali GE, Paulie S, Andersson G, et al. Number of interleukin-4- and interferon-gamma-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation. Eur J Immunol 1993; 23: 2740–5
- Böcher WO, Marcus H, Shakarchy R, et al. Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo. Immunology 1999; 96: 634–41
- Mayer S, Laumer M, Mackensen A, et al. Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay. Immunobiology 2002; 205: 282–9
- Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133–46
- Ma X, Chow JM, Gri G, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 1996; 183: 147–57
- Snijders A, Kalinski P, Hilkens CM, et al. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 1998; 10: 1593–8
- Hilkens CM, Kalinski P, de Boer M, et al. Human dendritic cells require exogenous interleukin-12- inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997; 90: 1920–6
- Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T–T help via APC activation. J Exp Med 1996; 184: 747–52
- Osada T, Nagawa H, Takahashi T, et al. Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response. Immunother 2002; 25: 176–84
- Li L, Masucci MG, Levitsky V. Effect of interleukin-7 on the in vitro development and maturation of monocyte derived human dendritic cells. Scand J Immunol 2000; 51: 361–71
- Li B, VanRoey MJ, Jooss K. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol 2007; 123: 155–65
- Semino C, Ceccarelli J, Lotti LV, et al. The maturation potential of NK cell clones toward autologous dendritic cells correlates with HMGB1 secretion. J Leukoc Biol 2007; 81: 92–9
- Dumitriu IE, Bianchi ME, Bacci M, et al. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007; 81: 84–91